
The U.S. plans to dump billions of flies from planes to fight a flesh-eating maggot
TOPEKA, Kansas — The U.S. government is preparing to breed billions of flies and dump them out of airplanes over Mexico and southern Texas to fight a flesh-eating maggot.
That sounds like the plot of a horror movie, but it is part of the government's plans for protecting the U.S. from a bug that could devastate its beef industry, decimate wildlife and even kill household pets. This weird science has worked well before.
'It's an exceptionally good technology,' said Edwin Burgess, an assistant professor at the University of Florida who studies parasites in animals, particularly livestock. 'It's an all-time great in terms of translating science to solve some kind of large problem.'
The targeted pest is the flesh-eating larva of the New World Screwworm fly. The U.S. Department of Agriculture plans to ramp up the breeding and distribution of adult male flies — sterilizing them with radiation before releasing them. They mate with females in the wild, and the eggs laid by the female aren't fertilized and don't hatch. There are fewer larvae, and over time, the fly population dies out.
It is more effective and environmentally friendly than spraying the pest into oblivion, and it is how the U.S. and other nations north of Panama eradicated the same pest decades ago. Sterile flies from a factory in Panama kept the flies contained there for years, but the pest appeared in southern Mexico late last year.
The USDA expects a new screwworm fly factory to be up and running in southern Mexico by July 2026. It plans to open a fly distribution center in southern Texas by the end of the year so that it can import and distribute flies from Panama if necessary.
Fly feeds on live flesh
Most fly larvae feed on dead flesh, making the New World screwworm fly and its Old World counterpart in Asia and Africa outliers — and for the American beef industry, a serious threat. Females lay their eggs in wounds and, sometimes, exposed mucus.
'A thousand-pound bovine can be dead from this in two weeks,' said Michael Bailey, president elect of the American Veterinary Medicine Association.
Veterinarians have effective treatments for infested animals, but an infestation can still be unpleasant — and cripple an animal with pain.
Don Hineman, a retired western Kansas rancher, recalled infected cattle as a youngster on his family's farm.
'It smelled nasty,' he said. 'Like rotting meat.'
How scientists will use the fly's biology against it
The New World screwworm fly is a tropical species, unable to survive Midwestern or Great Plains winters, so it was a seasonal scourge. Still, the U.S. and Mexico bred and released more than 94 billion sterile flies from 1962 through 1975 to eradicate the pest, according to the USDA.
The numbers need to be large enough that females in the wild can't help but hook up with sterile males for mating.
One biological trait gives fly fighters a crucial wing up: Females mate only once in their weekslong adult lives.
Why the U.S. wants to breed more flies
Alarmed about the fly's migration north, the U.S. temporarily closed its southern border in May to imports of live cattle, horses and bison and it won't be fully open again at least until mid-September.
But female flies can lay their eggs in wounds on any warm-blooded animal, and that includes humans.
Decades ago, the U.S. had fly factories in Florida and Texas, but they closed as the pest was eradicated.
The Panama fly factory can breed up to 117 million a week, but the USDA wants the capacity to breed at least 400 million a week. It plans to spend $8.5 million on the Texas site and $21 million to convert a facility in southern Mexico for breeding sterile fruit flies into one for screwworm flies.
How to raise hundreds of millions of flies
In one sense, raising a large colony of flies is relatively easy, said Cassandra Olds, an assistant professor of entomology at Kansas State University.
But, she added, 'You've got to give the female the cues that she needs to lay her eggs, and then the larvae have to have enough nutrients.'
Fly factories once fed larvae horse meat and honey and then moved to a mix of dried eggs and either honey or molasses, according to past USDA research. Later, the Panama factory used a mix that included egg powder and red blood cells and plasma from cattle.
In the wild, larvae ready for the equivalent of a butterfly's cocoon stage drop off their hosts and onto the ground, burrow just below the surface and grow to adulthood inside a protective casing making them resemble a dark brown Tic Tac mint. In the Panama factory, workers drop them into trays of sawdust.
Security is an issue. Sonja Swiger, an entomologist with Texas A&M University's Extension Service, said a breeding facility must prevent any fertile adults kept for breeding stock from escaping.
How to drop flies from an airplane
Dropping flies from the air can be dangerous. Last month, a plane freeing sterile flies crashed near Mexico's border with Guatemala, killing three people.
In test runs in the 1950s, according to the USDA, scientists put the flies in paper cups and then dropped the cups out of planes using special chutes. Later, they loaded them into boxes with a machine known as a 'Whiz Packer.'
The method is still much the same: Light planes with crates of flies drop those crates.
Burgess called the development of sterile fly breeding and distribution in the 1950s and 1960s one of the USDA's 'crowning achievements.'
Some agriculture officials argue now that new factories shouldn't be shuttered after another successful fight.
'Something we think we have complete control over — and we have declared a triumph and victory over — can always rear its ugly head again,' Burgess said.
John Hanna, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
8 hours ago
- CTV News
The U.S. plans to dump billions of flies from planes to fight a flesh-eating maggot
A worker drops New World screwworm fly larvae into a tray at a facility that breeds sterile flies in Pacora, Panama, in January 2024. (Panama-United States Commission for the Eradication and Prevention of Cattle Screwworms via AP) TOPEKA, Kansas — The U.S. government is preparing to breed billions of flies and dump them out of airplanes over Mexico and southern Texas to fight a flesh-eating maggot. That sounds like the plot of a horror movie, but it is part of the government's plans for protecting the U.S. from a bug that could devastate its beef industry, decimate wildlife and even kill household pets. This weird science has worked well before. 'It's an exceptionally good technology,' said Edwin Burgess, an assistant professor at the University of Florida who studies parasites in animals, particularly livestock. 'It's an all-time great in terms of translating science to solve some kind of large problem.' The targeted pest is the flesh-eating larva of the New World Screwworm fly. The U.S. Department of Agriculture plans to ramp up the breeding and distribution of adult male flies — sterilizing them with radiation before releasing them. They mate with females in the wild, and the eggs laid by the female aren't fertilized and don't hatch. There are fewer larvae, and over time, the fly population dies out. It is more effective and environmentally friendly than spraying the pest into oblivion, and it is how the U.S. and other nations north of Panama eradicated the same pest decades ago. Sterile flies from a factory in Panama kept the flies contained there for years, but the pest appeared in southern Mexico late last year. The USDA expects a new screwworm fly factory to be up and running in southern Mexico by July 2026. It plans to open a fly distribution center in southern Texas by the end of the year so that it can import and distribute flies from Panama if necessary. Fly feeds on live flesh Most fly larvae feed on dead flesh, making the New World screwworm fly and its Old World counterpart in Asia and Africa outliers — and for the American beef industry, a serious threat. Females lay their eggs in wounds and, sometimes, exposed mucus. 'A thousand-pound bovine can be dead from this in two weeks,' said Michael Bailey, president elect of the American Veterinary Medicine Association. Veterinarians have effective treatments for infested animals, but an infestation can still be unpleasant — and cripple an animal with pain. Don Hineman, a retired western Kansas rancher, recalled infected cattle as a youngster on his family's farm. 'It smelled nasty,' he said. 'Like rotting meat.' How scientists will use the fly's biology against it The New World screwworm fly is a tropical species, unable to survive Midwestern or Great Plains winters, so it was a seasonal scourge. Still, the U.S. and Mexico bred and released more than 94 billion sterile flies from 1962 through 1975 to eradicate the pest, according to the USDA. The numbers need to be large enough that females in the wild can't help but hook up with sterile males for mating. One biological trait gives fly fighters a crucial wing up: Females mate only once in their weekslong adult lives. Why the U.S. wants to breed more flies Alarmed about the fly's migration north, the U.S. temporarily closed its southern border in May to imports of live cattle, horses and bison and it won't be fully open again at least until mid-September. But female flies can lay their eggs in wounds on any warm-blooded animal, and that includes humans. Decades ago, the U.S. had fly factories in Florida and Texas, but they closed as the pest was eradicated. The Panama fly factory can breed up to 117 million a week, but the USDA wants the capacity to breed at least 400 million a week. It plans to spend $8.5 million on the Texas site and $21 million to convert a facility in southern Mexico for breeding sterile fruit flies into one for screwworm flies. How to raise hundreds of millions of flies In one sense, raising a large colony of flies is relatively easy, said Cassandra Olds, an assistant professor of entomology at Kansas State University. But, she added, 'You've got to give the female the cues that she needs to lay her eggs, and then the larvae have to have enough nutrients.' Fly factories once fed larvae horse meat and honey and then moved to a mix of dried eggs and either honey or molasses, according to past USDA research. Later, the Panama factory used a mix that included egg powder and red blood cells and plasma from cattle. In the wild, larvae ready for the equivalent of a butterfly's cocoon stage drop off their hosts and onto the ground, burrow just below the surface and grow to adulthood inside a protective casing making them resemble a dark brown Tic Tac mint. In the Panama factory, workers drop them into trays of sawdust. Security is an issue. Sonja Swiger, an entomologist with Texas A&M University's Extension Service, said a breeding facility must prevent any fertile adults kept for breeding stock from escaping. How to drop flies from an airplane Dropping flies from the air can be dangerous. Last month, a plane freeing sterile flies crashed near Mexico's border with Guatemala, killing three people. In test runs in the 1950s, according to the USDA, scientists put the flies in paper cups and then dropped the cups out of planes using special chutes. Later, they loaded them into boxes with a machine known as a 'Whiz Packer.' The method is still much the same: Light planes with crates of flies drop those crates. Burgess called the development of sterile fly breeding and distribution in the 1950s and 1960s one of the USDA's 'crowning achievements.' Some agriculture officials argue now that new factories shouldn't be shuttered after another successful fight. 'Something we think we have complete control over — and we have declared a triumph and victory over — can always rear its ugly head again,' Burgess said. John Hanna, The Associated Press


Globe and Mail
a day ago
- Globe and Mail
Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors'
Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors' Dallas, Texas - The Dr. Michael Rimlawi Scholarship for Future Doctors is now open for applications, offering a meaningful academic opportunity to undergraduate students across the United States who are committed to pursuing a career in medicine. Spearheaded by renowned spine surgeon Dr. Michael Rimlawi, this scholarship reflects a deep commitment to supporting the next generation of healthcare leaders who are ready to make a difference in the field of medicine. The scholarship is designed for undergraduate students enrolled at accredited colleges or universities who have set their sights on a future in healthcare. In line with Dr. Michael Rimlawi's dedication to innovation and mentorship in the medical field, the program encourages thoughtful reflection on personal inspiration and the impact future doctors wish to have in the profession. To be considered, applicants must submit an original essay between 500 and 750 words responding to the prompt: 'What inspired you to pursue a career in medicine, and how do you hope to make a difference in the field?' Essays will be evaluated on clarity, originality, and depth of insight. The deadline for application submissions is January 15, 2026, and the scholarship recipient will be announced on February 15, 2026. Dr. Michael Rimlawi, who is widely respected for his pioneering contributions in minimally invasive spine surgery, brings both clinical excellence and visionary leadership to the scholarship initiative. As a physician who has led advancements in micro-endoscopic techniques and was the first in the nation to perform the Globus Minimally Invasive XLIF procedure, Dr. Rimlawi understands the transformative impact of dedication and continuous learning in medicine. Through this scholarship, Dr. Michael Rimlawi aims to help lessen the financial burden for students who demonstrate not only academic determination but also a clear vision for how they intend to shape the healthcare system in meaningful ways. The scholarship is not limited by geographic region and is open to qualified undergraduate students throughout the United States. 'Mentoring future doctors has always been a personal mission,' says Dr. Michael Rimlawi, who has long advocated for educational support as a means to uplift future medical professionals. By launching this scholarship, Dr. Michael Rimlawi seeks to provide more than financial aid—he offers recognition and encouragement to students committed to advancing patient-centered care. The Dr. Michael Rimlawi Scholarship for Future Doctors continues to grow as an extension of Dr. Rimlawi's broader mission: to foster innovation, compassion, and progress within the healthcare system by investing in students who will become the physicians of tomorrow. Applicants interested in this opportunity are encouraged to visit the official website to review the full eligibility criteria and submit their essays through the application portal. For more details or to apply, visit below. Media Contact Company Name: Dr. Michael Rimlawi Scholarship Contact Person: Dr. Michael Rimlawi Email: Send Email City: Dallas State: Texas Country: United States Website:

National Post
a day ago
- National Post
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
Article content New benchmark confirms LENS ai 's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENS ai, powered by IPA's patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. Article content 'It's generally assumed that AI can only make accurate predictions if it has seen similar data before,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'But this benchmark proves otherwise: LENS ai accurately mapped antibody binding sites on entirely new antibody – protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn't always need massive data to be powerful and accurate – it just needs the right kind.' Article content LENS ai Epitope Mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins – helping scientists design better treatments faster. Unlike traditional methods that take months and require lab work, LENS ai delivers results in hours – using just the digital sequences – cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments. Article content In a new benchmark study, LENS ai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. Despite having no prior exposure to these molecules, LENS ai achieved prediction scores nearly identical to those from its original training data. This score, known as AUC (Area Under the Curve), is a widely accepted measure of accuracy in computational biology. Article content The consistent performance on entirely new, unseen complexes confirms that LENS ai 's artificial intelligence can reliably analyze and predict antibody binding – even for molecules outside its training set. This breakthrough demonstrates LENS ai 's power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery. Article content Why This Benchmark Matters Article content In the new study, LENS ai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples – proving true generalization, not memorization. Because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays. Article content What It Means for Partners and Investors Article content With LENS ai already embedded in collaborations across big pharma and biotech, ImmunoPrecise is scaling access through secure APIs and custom partnerships. The platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets – positioning the company and its investors at the forefront of AI-driven antibody therapeutics. Article content For more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of LENS ai Epitope Mapping. Article content ai Article content 's breakthrough ability to accurately map binding sites on a completely Article content 'unseen' target Article content , with no prior exposure to the antibody, the antigen, or their structure. Article content These examples underscore how LENS ai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness. Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the LENSai™ and HYFT® platforms; the generalizability of the Company's AI models to novel therapeutic targets; the role of AI in accelerating antibody discovery; and the Company's future scientific, commercial, and strategic developments. Article content Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for AI-driven therapeutic platforms. Article content Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at Article content Article content and EDGAR profile at Article content Article content ). Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Article content Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. Article content Article content Article content Article content Contacts Article content Investor Relations Contact Article content Article content Article content Article content